Advances in Pharmacogenetics in Primary Care - Canadian Council On Continuing Education In Pharmacy (CCCEP)
This eCME is directed to primary care clinicians (family physicians, nurse practitioners and pharmacists) in the therapeutic area of pharmacogenetic testing and personalized medicine. This one-hour program will be accredited through the CFPC and CCCEP. Pharmacogenomics (PGx) focuses on understanding how genes affect individual responses to medications, i.e., the relationship between drug responses and genetic variants. PGx testing provides objective data about specific aspects of an individual’s genetic makeup that may predict an individual’s response to medications. For example, the liver enzyme CYP2D6 is involved in metabolizing a quarter of all prescriptions and exists in more than 160 known variants. Some variants can negatively impact how particular drugs are metabolized by individuals who carry the variants.
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.5 CEU(s). CCCEP File Number: 1066-2018-2652-I-P
Moe Abdallah, BSc., BSc. Pharm., R.Ph.
John Axler, MD, CCFP, FCFP
Jahed Khoshnood, BSc, PharmD, RPh
Daniel Mueller, MD, PhD
John Papastergiou, BSc Phm, RPh
Sol Stern, MD, MCFP
Deanna Telner, MD, CCFP
Upon completion of the program, participants will be able to:
- Summarize the benefits and challenges of pharmacogenetic testing;
- Identify key variables that should be considered for precision prescribing and why precision prescribing should include more than pharmacogenetics;
- Explain how knowledge of an individual’s genetic variants may impact choice and/or dosage of medications;
- Identify three scenarios in which pharmacogenetic testing may impact treatment choices;
- Discuss how you might counsel patients about pharmacogenetic testing and the importance of proper interpretation of the results by a healthcare provider.